Immunome (IMNM) Retained Earnings (2019 - 2026)

Immunome (IMNM) has 8 years of Retained Earnings data on file, last reported at $1.4 billion in Q1 2026.

• Quarterly Retained Earnings rose 58.55% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 58.55% YoY) and the FY2025 annual result came in at $1.4 billion, up 364.17% from the prior year.
• Retained Earnings advanced to $1.4 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.4 billion in Q1 2026 to a low of -$658.3 million in Q3 2025.
• A 5-year average of $166.6 million and a median of -$99.7 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2024 — Retained Earnings tumbled 362.65% — and 2025, when it jumped 43504500.0%.
• Tracing IMNM's Retained Earnings over 5 years: stood at -$116.0 million in 2022, then sank by 92.07% to -$222.8 million in 2023, then tumbled by 131.49% to -$515.8 million in 2024, then soared by 364.17% to $1.4 billion in 2025, then grew by 0.6% to $1.4 billion in 2026.
• The last three Retained Earnings figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and -$658.3 million (Q3 2025), per Business Quant data.